University of Chicago, Department of Pharmaceutical Services, IL 60637, USA.
Expert Opin Pharmacother. 2009 Dec;10(18):3091-102. doi: 10.1517/14656560903436493.
Pazopanib (Votrient, GW786034) is a potent pan-VEGF inhibitor in advanced clinical development. Like other orally available VEGFR inhibitors, pazopanib is clinically efficacious and well tolerated. The recently reported Phase III clinical trial in metastatic renal cell carcinoma showed activity similar to approved agents with variations in toxicity which has led to its recent FDA approval. Given the growing number of agents in this category, differences not only in single-agent activity but also toxicity and combinatorial potency will probably distinguish pazopanib from other similar agents.
帕唑帕尼（Votrient，GW786034）是一种在临床开发中具有强大的泛 VEGF 抑制剂。与其他口服可用的 VEGFR 抑制剂一样，帕唑帕尼在临床上有效且耐受性良好。最近报道的转移性肾细胞癌的 III 期临床试验显示，其活性与已批准的药物相似，但毒性存在差异，这导致了其最近获得 FDA 的批准。鉴于该类别中的药物数量不断增加，不仅在单药活性方面，而且在毒性和组合效力方面的差异可能会使帕唑帕尼与其他类似药物区分开来。
